The FDA approved the combination of durvalumab (Imfinzi) plus FLOT chemotherapy (fluorouracil, leucovorin, oxaliplatin, and ...
Misconceptions often delay diagnosis and treatment, allowing the disease to progress unnoticed. It is therefore critical to separate myth from fact so people can recognise early symptoms and seek ...
Drug approvals this year have reflected the trend in clinical development of biologics shifting from intravenous to ...
Diffuse large B-cell lymphoma (DLBCL) is an aggressive blood cancer that kills most untreated patients within one year. Standard CHOP chemotherapy improves five-year survival to 70%—still a ...
First-line use of encorafenib and binimetinib in BRAF V600E NSCLC recorded a median overall survival of 47.6 months, according to data presented at the ESMO congress.
Lung cancer is no longer solely a smoker's disease, with air pollution emerging as a significant risk factor affecting ...
The FDA approved perioperative durvalumab (Imfinzi) in combination with a multidrug chemotherapy regimen for resectable ...
The subcutaneous formulation of toripalimab demonstrated noninferior pharmacokinetics compared to the intravenous version in ...
This partnership demonstrates the importance of multi-stakeholder engagement in addressing one of Canada's most urgent health challenges. By driving awareness and igniting innovation, Lung Cancer ...
Discover why Ideaya Biosciences, Inc. is rated a Buy for its promising oncology pipeline and upcoming catalysts. Click for my ...
Unusually, Firebrick Pharma has shared the results of an investor survey that doesn't entirely cast the company in a ...
The PACIFIC-2 trial reveals that durvalumab with chemoradiotherapy offers no survival benefits for stage 3 NSCLC and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback